Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trialMathias Rummel, Wolfram Brugger, Dorothea Kofahl-Krause et al.|The Lancet|2013Cited by 1.5k
Role of Epidermal Growth Factor Inhibition in Experimental Pulmonary HypertensionBhola K. Dahal, Ralph T. Schermuly, Teodora Cornitescu et al.|American Journal of Respiratory and Critical Care Medicine|2009Cited by 131
Subanalysis of the StiL NHL 1–2003 Study: Achievement of Complete Response with Bendamustine-Rituximab (B-R) and CHOP-R in the First-Line Treatment of Indolent and Mantle Cell Lymphomas Results in Superior Survival Compared to Partial Response.Mathias Rummel, Wolfram Brugger, N. Niederle et al.|Blood|2012Cited by 2